Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours

Investigation of the Pharmacokinetics of a Transtec® 35 µg/h Transdermal Patch Application for 96 Hours and a Patch Application for 72 Hours in an Open, Randomised, Single Application, Two-period Crossover, Phase I Study in 30 Healthy Male Volunteers

The purpose of the study was to investigate the pharmacokinetics (i.e. the uptake, distribution and elimination from the body) of dermally applied buprenorphine during and after different application periods, i.e., a 96-hour and a 72-hour application of the Transtec (Registered Trademark) patch (release rate 35 micrograms per hour [µg/hour]). In the Transtec summary of product characteristics (prescribing information for the physician), the wearing time per patch is restricted to three days (72 hours) after which the patch has to be replaced. However, market experience has shown that the Transtec patches are sometimes worn for a period longer than three days, i.e. they sometimes happen to be only replaced every four days. There was currently no data available as how to evaluate this longer wearing period.

Study Overview

• Status: Completed
• Conditions: Pain; Pharmacokinetics
• Intervention / Treatment: Drug: Transtec 35 µg/hour transdermal patch

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Grünstadt, Germany, 67269
    • Institut für Klinische Pharmakologie Bobenheim

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Male Caucasian volunteers, aged 25-45 years.
• Body mass index (BMI) between 18 and 30 kilogram/squared meter (extremes included).
• Good physical and mental health status (no current acute illness) determined on the basis of the medical history and a general clinical examination.
• Systolic blood pressure between 90 millimeter mercury (mmHg) and 150 mmHg (extremes included).
• Diastolic blood pressure between 45 mmHg and 90 mmHg (extremes included).
• Pulse rate between 45 beats per minute (bpm) and 100 bpm (extremes included).
• Electrocardiogram (12 lead) considered as normal by the investigator.
• Results of laboratory tests within the normal ranges for the testing laboratory. The investigator may include a participant having values outside the accepted range if, in his/her opinion, these values are of no clinical relevance. The decision will be justified.
• The participant has been informed using the informed consent approved by the local ethics committee.
• The consent was obtained by participant's signature.

Exclusion Criteria:

• Diseases and functional disorders of the central nervous system (CNS), endocrinological system, gastrointestinal tract, hepatobiliary system, renal system, respiratory system or cardiovascular system including marked repolarization abnormality (e.g. suspicious or definite congenital long QT syndrome) or co-medication that is known to influence cardiac repolarization substantially.
• History of seizures or at risk (i.e. head trauma, epilepsy in family anamnesis, unclear loss of consciousness).
• Malignancy.
• History of orthostatic hypotension.
• Positive human immunodeficiency virus (HIV) 1/2-antibodies, hepatitis B surface (HBs) -antigen, hepatitis B core (HBc) -antibodies, hepatitis C virus (HCV) -antibody tests at the screening examination.
• Drug allergy.
• Bronchial asthma.
• Participation in another clinical study within three month prior to the start of this study (exception: characterization of metabolizer status).
• Blood donation (more than 100 milliliters) within three month prior to the start of this study.
• Use of any medication within four weeks prior to the start of the study (self-medication or prescription).
• Evidence of alcohol, medication or drug abuse.
• Positive Naloxone challenge test.
• Positive drug abuse screening test.
• Extremely unbalanced diet (in the opinion of the investigator).
• Excessive consumption of food or beverages containing caffeine or other xanthines (more than five cups of coffee or equivalent per day).
• Smoking of more than 20 cigarettes per day.
• Neurotic personality, psychiatric illness or suicide risk.
• Known or suspected of not being able to comply with the study protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Treatment A: Transtec patch application for 96 hours; Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.	Drug: Transtec 35 µg/hour transdermal patch; Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
EXPERIMENTAL: Treatment B: Transtec patch application for 72 hours; Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.	Drug: Transtec 35 µg/hour transdermal patch; Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic parameter: AUC48-72 for buprenorphine	Partial area under the plasma concentration-time curve (from 48 hours after application until 72 hours after application).	From 48 hours to 72 hours
Pharmacokinetic parameter: AUC72-96 for buprenorphine	Partial area under the plasma concentration-time curve (from 72 hours after application until 96 hours after application).	From 72 hours to 96 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic parameter: Cmax for buprenorphine	Maximum observed plasma concentration of the measured concentration-time profile. Blood samples will be taken for the determination of buprenorphine plasma concentrations at distinct time points: Before application to 144 hours after patch application. If the patch was applied for 96 hours, additional samples were taken at 156 and 168 hours after application. For the analysis of buprenorphine in human plasma, a validated liquid chromatography mass spectrometry (LC/MS/MS)-method will be used.	Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours
Pharmacokinetic parameter: tmax for buprenorphine	Time of maximum concentration, time after transdermal patch application at which Cmax occurs.	Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours
Pharmacokinetic parameter: AUC0-t for buprenorphine	Area under plasma concentration-time curve from application until the last sampling point (t) with a quantifiable concentration, calculated by the linear/log trapezoidal method, i.e., the linear trapezoidal rule is applied up to Cmax and then the log trapezoidal rule is applied for the remainder of the curve.	Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours
Pharmacokinetic parameter: t1/2z for buprenorphine	Apparent terminal elimination half-life.	Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours
Pharmacokinetic parameter: AUC0-inf for buprenorphine	Area under the plasma concentration-time curve extrapolated to infinity.	Before application and after 4, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104,112,120,132,144,156, and 168 hours
Incidence of treatment emergent adverse events	Number of adverse events and number of participants with adverse events.	From patch application (Day 1) until Final check (Day 12)
Characteristics of treatment emergent adverse events	Adverse events with information on intensity, seriousness, relationship to the investigational product, outcome and action taken will be determined.	From patch application (Day 1) until Final check (Day 12)
Onset and duration of treatment emergent adverse events	Adverse events with information on onset and duration to the investigational product will be determined.	From patch application (Day 1) until Final check (Day 12)

Collaborators and Investigators

• Sponsor: Grünenthal GmbH

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 5, 2004
• Primary Completion (ACTUAL): May 26, 2004
• Study Completion (ACTUAL): May 26, 2004

Study Registration Dates

• First Submitted: December 7, 2018
• First Submitted That Met QC Criteria: December 7, 2018
• First Posted (ACTUAL): December 10, 2018

Study Record Updates

• Last Update Posted (ACTUAL): December 10, 2018
• Last Update Submitted That Met QC Criteria: December 7, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Other Study ID Numbers: HP5303/04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No